The main point of investing for the long term is to make money. But more than that, you probably want to see it rise more than the market average. But Abbott Laboratories (NYSE:ABT) has fallen short of that second goal, with a share price rise of 16% over five years, which is below the market return. Looking at the last year alone, the stock is up 9.7%.
Let’s take a look at the underlying fundamentals over the longer term, and see if they’ve been consistent with shareholders returns.
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
During five years of share price growth, Abbott Laboratories achieved compound earnings per share (EPS) growth of 33% per year. This EPS growth is higher than the 3% average annual increase in the share price. So it seems the market isn’t so enthusiastic about the stock these days.
You can see below how EPS has changed over time (discover the exact values by clicking on the image).
We know that Abbott Laboratories has improved its bottom line lately, but is it going to grow revenue? If you’re interested, you could check this free report showing consensus revenue forecasts.
What About Dividends?
When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. We note that for Abbott Laboratories the TSR over the last 5 years was 27%, which is better than the share price return mentioned above. And there’s no prize for guessing that the dividend payments largely explain the divergence!
A Different Perspective
Abbott Laboratories shareholders gained a total return of 12% during the year. Unfortunately this falls short of the market return. On the bright side, that’s still a gain, and it’s actually better than the average return of 5% over half a decade This could indicate that the company is winning over new investors, as it pursues its strategy. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Abbott Laboratories is showing 1 warning sign in our investment analysis , you should know about…